IJR vs XBI
iShares Core S&P Small-Cap ETF vs SPDR S&P Biotech ETF
- • IJR has the lower expense ratio at 0.06% vs 0.35% for XBI.
- • IJR pays a higher dividend yield (1.22%).
Side-by-side metrics
| Metric | IJR | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.06% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.22% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $105.58B | $10.92B |
YTD return | 18.90% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.07 | 1.01 |
P/E ratio | 17.17 | — |
Last price | $142.33 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
IJR top holdings
| XTSLA | BlackRock Cash Funds Treasury SL Agency | 1.19% |
| GKOS | Glaukos Corp | 0.80% |
| VSAT | Viasat Inc | 0.60% |
| PAYC | Paycom Software Inc | 0.58% |
| SM | SM Energy Co | 0.55% |
| MTCH | Match Group Inc Ordinary Shares - New | 0.54% |
| PTGX | Protagonist Therapeutics Inc | 0.53% |
| RHP | Ryman Hospitality Properties Inc | 0.52% |
| TGTX | TG Therapeutics Inc | 0.49% |
| LTH | Life Time Group Holdings Inc | 0.49% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About IJR
IJR (iShares Core S&P Small-Cap ETF) is Tracks the S&P SmallCap 600 index. Managed by iShares, the fund carries $105.6B in assets under management, an expense ratio of 0.06%, a dividend yield of 1.22%. Its largest holding is BlackRock Cash Funds Treasury SL Agency (XTSLA), which represents 1.2% of the portfolio. Real Estate is the fund's largest sector exposure at 7.4%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.